Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension

被引:165
|
作者
Taddei, S
Virdis, A
Ghiadoni, L
Magagna, A
Salvetti, A
机构
关键词
hypertension; endothelium; nitric oxide; endothelium-derived factors; indomethacin;
D O I
10.1161/01.HYP.29.1.274
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
To evaluate whether cyclooxygenase constrictor substances can impair nitric oxide-mediated vasodilation in essential hypertension, in seven normotensive subjects (43.3+/-4.1 years; BP, 117+/-6/81+/-2 mm Hg) and seven essential hypertensive patients (47.1+/-5.2 years; BP, 151+/-8/98+/-4 mm Hg) we studied forearm blood flow (strain-gauge plethysmography) modifications induced by intrabrachial acetylcholine (0.15, 0.45, 1.5, 4.5, 15 mu g . 100 ml(-1) . min(-1)) in basal conditions, during infusion of N-G-monomethyl-L-arginine (L-NMMA; 100 mu g . 100 mL(-1) . min(-1)), a nitric oxide synthase inhibitor, or indomethacin (50 mu g . 100 mL(-1) . min(-1)), a cyclooxygenase inhibitor, or simultaneous indomethacin and L-NMMA. In normotensives, vasodilation to acetylcholine was blunted by L-NMMA (maximum flow increase: 671+/-64% and 386+/-42%, respectively; P<.01),and this effect was unchanged by indomethacin. In contrast, in hypertensive patients, vasodilation to acetylcholine (maximum flow increase: 458+/-33%) was unchanged by L-NMMA. Indomethacin significantly (P<.01) increased the response to acetylcholine (maximum flow increase: 635+/-53%) and restored the inhibitory effect of L-NMMA (maximum flow increase: 445+/-36%; P<.01 versus indomethacin alone). In an adjunctive seven normotensives (51.4+/-4.2 years; BP, 114+/-5/79+/-3 mm Hg) and seven essential hypertensives (53.2+/-7.6 years; BP, 153+/-9/100+/-3 mm Hg) we repeated the same protocol by replacing L-NMMA with L-arginine (200 mu g . 100 mL(-1) . min(-1)), the substrate for NO synthase. In normotensives, vasodilation to acetylcholine was increased by L-arginine (maximum flow increase: 539+/-48% and 806+/-61%, respectively) and this effect was unchanged by indomethacin. In hypertensive patients, vasodilation to acetylcholine (maximum flow increase: 339+/-32%) was unchanged by L-arginine but was significantly (P<.01) increased by indomethacin (maximum flow increase: 592+/-38%). Moreover, indomethacin restored the facilitatory effect of L-arginine (maximum flow increase: 804+56%; P<.01 versus indomethacin alone). Therefore, cyclooxygenase inhibition restores nitric oxide-mediated vasodilation in essential hypertension, suggesting that cyclooxygenase-dependent substances can impair nitric oxide production.
引用
收藏
页码:274 / 279
页数:6
相关论文
共 50 条
  • [1] Cyclooxygenase inhibition restores nitric oxide mediated vasodilation in the forearm of essential hypertensive patients.
    Taddei, S
    Virdis, A
    Ghiadoni, L
    Salvetti, A
    HYPERTENSION, 1996, 28 (03) : P143 - P143
  • [2] Endothelial Nitric Oxide Synthase, Cyclooxygenase-2, and Essential Hypertension: Is There an Interaction?
    Tsikas, Dimitrios
    Stichtenoth, Dirk O.
    HYPERTENSION, 2013, 62 (04) : E15 - E15
  • [3] Cyclooxygenase inhibition decreases nitric oxide synthase activity in human platelets
    Chen, LY
    Salafranca, MN
    Mehta, JL
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1997, 273 (04): : H1854 - H1859
  • [4] Response to Endothelial Nitric Oxide Synthase, Cyclooxygenase-2, and Essential Hypertension: Is There an Interaction?
    Virdis, Agostino
    Bacca, Alessandra
    Colucci, Rocchina
    Duranti, Emiliano
    Fornai, Matteo
    Materazzi, Gabriele
    Ippolito, Chiara
    Bernardini, Nunzia
    Blandizzi, Corrado
    Bernini, Giampaolo
    Taddei, Stefano
    HYPERTENSION, 2013, 62 (04) : E16 - E16
  • [5] Nitric oxide synthase-inhibition hypertension is associated with altered endothelial cyclooxygenase function
    Bratz, IN
    Kanagy, NL
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2004, 287 (06): : H2394 - H2401
  • [6] EFFECTS OF NITRIC-OXIDE AND CYCLOOXYGENASE INHIBITION ON SPLANCHNIC HEMODYNAMICS IN PORTAL-HYPERTENSION
    WU, YP
    BURNS, RC
    SITZMANN, JV
    HEPATOLOGY, 1993, 18 (06) : 1416 - 1421
  • [7] Is central nitric oxide essential in hypertension?
    Pointer, MA
    JOURNAL OF HYPERTENSION, 2005, 23 (09) : 1637 - 1638
  • [8] NITRIC-OXIDE INHIBITION IN HYPERTENSION
    LAHERA, V
    KHRAIBI, AA
    NEWS IN PHYSIOLOGICAL SCIENCES, 1994, 9 : 268 - 271
  • [9] Arterial hypertension and inhibition of nitric oxide
    Zadorin, E
    Amosova, E
    Konoplyova, L
    Gubskij, U
    HYPERTENSION, 2004, 44 (04) : 587 - 587
  • [10] ALTERED PLATELET NITRIC-OXIDE SYNTHASE ACTIVITY IN ESSENTIAL-HYPERTENSION
    CADWGAN, TM
    BENJAMIN, N
    HYPERTENSION, 1992, 20 (03) : 399 - 399